Regulatory milestones

Biogen Idec Inc. (NASDAQ:BIIB) gained $2.90 to $315.54 last week after the European Commission approved an MAA for Tecfidera dimethyl fumarate as first-line treatment for relapsing-remitting multiple sclerosis (RRMS). The company said it plans to launch the product in the EU in the coming weeks.